💡 #EANO2026 is around the corner, and we are very proud to present this year’s EANO Ambassadors! Follow them on LinkedIn and/or Bluesky for a range of expert insights, and join the conversation using the official hashtag #EANO2026. We look forward to meeting you all in #Rome! #NeuroOncology #btsm

Finally out: academic.oup.com/neuro-oncolo...

Point/counterpoint: The use of perfusion-weighted MRI and amino acid PETfor the identification of treatment-related changes

Lay Summary. Accurately differentiating actual tumor progression from treatment-related changes, such as pseudoprogression or radiation-induced injury, rem

academic.oup.com

Please join: www.events-communication.com/event/gliobl...

📸 Throwback Thursday: EANO Seminars 2026 in Bucharest – multidisciplinary, patient-centred neuro-oncology and inspiring exchange across disciplines. Thank you to all contributors for an inspiring exchange! #EANO #NeuroOncology #CNS #EANOSeminars2026 #TBT

🙌 Insightful discussions today in Bucharest at the #EANO Tumor Board 2026. Real-world cases and expert lectures highlighted the importance of multidisciplinary collaboration in improving care for patients with #glioma. Supported by an unrestricted educational grant from Servier. #NeuroOncology

x.com/aacr/status/...

We’re pleased to welcome Martin van den Bent, MD, PhD, as an adjunct professor! In addition to mentoring faculty and residents, he is helping increase UCSF’s role in large international clinical trials: braintumorcenter.ucsf.edu/news/new-neu... @eanoassociation.bsky.social @erasmusmc.bsky.social

The full article “Long-term outcomes of active surveillance after #DOTATATE PET/MRI–confirmed gross total resection in WHO grade 2 #meningioma” is now available. Read the article in #NeuroOncology Advances: bit.ly/4qQR4gn

Read the new article in #NatureMedicine evaluating the efficacy of #abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, for #meningiomas with somatic NF2 or CDK pathway alterations. go.nature.com/4jL77cZ

📣 Join the 4th Annual EANO/SNO Highlights Webinar Top abstracts from #EANO2025 (Prague) & #SNO2025 (Honolulu) – latest advances in neuro-oncology. 🗓 Feb 6, 2026 | ⏰ 18:30–19:30 CET 🎟 Free for #EANO & #SNO members 👉 Register now: bit.ly/EANO-SNO-2025 #NeuroOncology @neuroonc.bsky.social

📃Just published in JNM: our recent study showing the clinical value of FET PET to identify early response to Regorafenib in patients with #glioma. 🔗: jnm.snmjournals.org/content/earl... Thanks to @galldiks.bsky.social, @ph-lohmann.bsky.social and co-authors. #aminoacidPET #braintumor

The joint #ICOM-#BIMS (British Irish Meningioma Society) #meningioma session will be held as part of the 100th Anniversary Meeting of @The_SBNS. Find out more about #SBNS100 here: bit.ly/4pvKifo

#EANO2025 in Prague 🇨🇿 – the highlights. One of our most successful meetings yet: record abstracts, outstanding multidisciplinary science, strong early-career engagement, and for the first time patient representatives. #NeuroOncology. 🎥 youtu.be/CWuMWef_mmI See you in Rome for #EANO2026 🇮🇹

EANO Meeting 2025 in Prague

YouTube video by EANO

youtu.be

💫 Warm seasonal greetings to our #EANO community! 2025 highlighted the strength and collaboration of #NeuroOncology –made possible by your engagement and support. Wishing you joyful holidays and an inspiring New Year as we look ahead to EANO Seminars and Rome 2026. Übersetzung anzeigen

📣 EANO Seminars 2026 – one week left to apply! The next #EANO seminars will take place in Bucharest, Romania, on March 13–14, 2026. 🗓️ Application deadline: December 10, 2025 👉 Learn more and apply today: www.eano.eu/eanoseminars... #EANO #EANO2026 #NeuroOncology #BrainTumour #CNS

That’s a wrap on WFNOS/SNO 2025 in Honolulu, Hawaii! The #EANO team truly enjoyed connecting with colleagues from around the world, exchanging insights, and celebrating SNO’s 30th anniversary. A big thank you to the @neuroonc.bsky.social for hosting this inspiring meeting! 🌺 #SNO2025 #WFNOS2025

Start of the Educational Day of #SNO2025 and WFNOS2025. Welcoming by @mjlimfat.bsky.social. Looking forward to an inspiring conference in Honolulu. @neuroonc.bsky.social @eanoassociation.bsky.social

Awarded as best clinical science poster at #EANO2025 and now published online: "Clinical potential of [18F]FET PET in patients with circumscribed astrocytic glioma" by @jmwerner.bsky.social and colleagues. 👉 link.springer.com/article/10.1... #NuclearMedicine #Glioma #NeuroOncology #PETImaging

Can DNA methylation risk groups unlock personalized radiotherapy decisions in meningioma? Our new paper provides the clinical framework — thanks to all collaborators! @neuroonc.bsky.social @eanoassociation.bsky.social @gelarehzadeh.bsky.social @icomeningioma.bsky.social doi.org/10.1093/neuo...

A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma

AbstractBackground. DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patien

doi.org

Are you a physician, nurse, researcher, technician, or allied health professional with an interest in #NeuroOncology? Join the next #EANO Seminars, taking place in Bucharest, RO, on March 13–14, 2026! - Application deadline: December 10, 2025 - Learn more & apply here: 👉 www.eano.eu/eanoseminars...

Outstanding oral presentation at #EANO2025 in Prague, now published in #NeuroOncology: the Multicenter Randomized Phase II Study of R-MPV-A #Chemoimmunotherapy With or Without Low-Dose Whole-Brain #Radiotherapy for Newly-Diagnosed Primary... by Antonio Omuro & colleagues. 👉 doi.org/10.1093/neuo...

The opening of registrations and abstract submission is just around the corner for the EACR 2026 Annual Congress, so what better time to reflect on our Travel Grant winners' experiences of EACR 2025 that took place earlier this year in Lisbon, Portugal. Read more: magazine.eacr.org/eacr-2025-co...

Exciting times for #EANO! We’re delighted to welcome Roberta Rudà from the University of Turin as President Elect of EANO. Together, we look forward to continuing our mission of advancing science, innovation, and collaboration in #NeuroOncology.

“Long-Term Outcomes of Active Surveillance After DOTATATE PET/MRI–Confirmed Gross Total Resection in WHO Grade 2 #Meningioma” is now available in NOA as an accepted manuscript: academic.oup.com/noa/advance-...

🎗️ EANO proudly supports the 2025 International Brain Tumour Awareness Week! Let’s raise awareness, support patients, and promote advancements in research in #NeuroOncology. Together, we can make a difference! #EANO #BrainTumourAwareness #btsm #BrainTumours

Read the oral abstract poster from August aiming to identify chromosomal copy number alterations which could be used to improve the current CNS WHO grading of meningioma. Read more in @EditorNeuro: bit.ly/4ng5d4m

Read the Cancer Discovery Piece: Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine by @viveksubbiah.bsky.social doi.org/10.1158/2159...

I-Mei@i-mei.bsky.social · 11mo ago

Great #ESMO25 talk by @viveksubbiah.bsky.social on targeting molecular drivers of cancer in a tissue-agnostic manner: for more of his thoughts, check out his @aacrjournals.bsky.social Cancer Discovery piece (online as of October 17) here:

Read the letter to the editor ‘PAS+/PASD- intracytoplasmic glycogen is not specific for clear cell #meningioma’ published in the Journal of #Neuropathology & Experimental #Neurology: bit.ly/4986hUr

Congratulations to our #EANO2025 award winners for Best Poster Presentation: @jmwerner.bsky.social (Clinical research), Elisabetta Mori (Basic research), Thomas Millner (Translational research), Jan Coburger (Supportive care and quality of life research)! 👏 #NeuroOncology #EANO